ABSTRACT
INTRODUCTION
Generalized Anxiety Disorder (GAD) is a chronic and prevalent mental disorder that causes high morbidity and personal suffering. Benzodiazepines are the most frequently used drugs to treat GAD, although buspirone and antidepressants are also employed (Andreatini et al., 2001) . While these drugs are effective, they present several problems, such as the amnesic effect of benzodiazepines (Izquierdo and Medina, 2001 ) and some tricyclic antidepressants (Amado-Boccara et al, 1995) . Moreover, there is only a partial tolerance to the deleterious effect of benzodiazepines even with chronic use (Gorenstein et al., 1995) . Phytomedicines are an interesting alternative to synthetic drugs for therapy (e.g. Goluart et al., 2005) and they offer the potential for the development of distinctly new drugs (Calixto, 2000; Carlini, 2003) . Among the several phytomedicines studied as potential anxiolytics, Piper methysticum, Passiflora incarnata, Passiflora actinia, Passiflora alata and Valeriana officinalis showed some anxiolytic effect (Oga et al., 1984; Wong et al., 1998; Akhondzadeh et al., 2001; Dhawan et al., 2001a; Dhawan et al., 2001b; Andreatini et al., 2002; Dhawan et al., 2004; Santos et al., 2006) . More specifically, a plant extract combination containing Passiflora incarnata and Valeriana officinalis showed an anxiolytic clinical effect (Bourin et al., 1997) . A combination of a hydroethanolic extract of Passiflora alata Dryander and Valeriana officinallis L. (CPV, 20 mg/kg) showed an anxiolytic effect in the elevated plus-maze after repeated (15 days), but not acute, treatment . Recently, Tabach et al. (2009) also found an anxiolytic-like effect with a phytotherapeutic product containing Passifora incarnata L., Valeriana officinalis L., and Crataegus oxycantha L., a result that reinforced the putative anxiolytic-like effect of CPV. However, to improve the drug armamentarium for the treatment of anxiety, besides an anxiolytic effect a new drug should also be devoid of some adverse effects of the standard anxiolytics, such as memory impairment (Andreatini et al., 2001) . Habituation can be defined as a decrease of a behavioral response after a repeated exposure (Platel and Porsolt, 1982) . Habituation can be measured as the difference between the exploratory activity observed in two serial experimental sessions in the same apparatus (Platel and Porsolt, 1982; Ukai et al., 1994) . The increase in the horizontal activity (ambulation) in the second session is a better measure of memory than the vertical activity, e.g., rearing (Ukai et al., 1994) . Inhibitory avoidance is a procedure based on the association of a behavior with an unpleasant event leading to a hesitation to exhibit this behavior on the next occasion. In the step-through procedure, the latency to enter the dark compartment to avoid a footshock is measured (Sahgal, 1993) . In animal models of memory, the time of drug administration is an important experimental variable. Although the post-training administration can be more clearly interpreted in terms of impairment or improvement of memory consolidation, avoiding a change in the alertness or motivation (Platel and Porsolt, 1982) , in the clinical setting, the anxiolytic drugs are used to exert their effect during the day. Besides, the amnesic effect of benzodiazepine anxiolytics is observed with pre-training, but not post-training administration (Izquierdo and Medina, 2001) . In this way, pre-training drug administration models the clinical situation more closely than posttraining administration. Therefore, with the aim to study the effect of CPV on memory in a similar pattern to the clinical use of an anxiolytic drug, the animal performance after the drug administration was evaluated in this work. The aim of the present study was to determine whether the CPV had a benzodiazepine (diazepam)-like amnesic effect using two mouse models: the habituation to a new environment, and the inhibitory avoidance.
MATERIAL AND METHODS

Animals
Animals were adult male Swiss mice (60-90 days old) from the breeding colony, weighing between 20 and 25 g. They were housed in polypropylene cages with wood shavings as bedding, under controlled conditions of light (12 h light-dark cycle, lights on at 7:00 a.m.) and temperature (22 ± 2°C). The animals had free access to water and food throughout the experiment.
Drugs and Treatment
Diazepam (Cristália, Brazil) at 1.0 and 2.5 mg/kg (i.p., at constant volume of 10 ml/kg) was used as positive control. The phytotherapeutic compound (CPV) consisted of a combination of hydroethanolic extract from Passiflora alata Dryander leaves and Valeriana officinalis L. roots (1.7 ml/1.0 ml respectively) and had a final composition of 65% ethanol and 9.3% dry residue. This combination was standardized at 0.044% of valerenic acid and 0.1062 of vitexina . The dry residue (Herbarium Laboratório Botânico) was re-suspended in deionized water immediately before the experiments. CPV and its vehicle were administered p.o. at a constant volume of 10 ml/kg. The vehicle of the diazepam and CPV were used as negative controls.
Apparatus
Spontaneous Locomotor Activity Chamber
The locomotor activity of each animal was measured with photocell-equipped activity chambers (Plexiglas cages, 40 x 25 x 20 cm), with a grid floor made of stainless steels bars (spaced 1.0 cm apart) and provided with three photocells (spaced 10 cm apart and at a height of 1.5 cm). The luminosity of the chamber during the experiments was 0.57 lux (Camarini et al., 1995) .
Inhibitory Avoidance
The inhibitory avoidance test apparatus was an automated shuttle box (GEMINI Avoidance System, San Diego Instruments, San Diego, CA) with a dark glass front and a floor made of parallel 2-mm diameter stainless-steel bars spaced 8-mm apart. The box (23 x 50 x 23 cm) was divided into an illuminated compartment and a dark compartment of the same size separated by a wall with a guillotine door (6 x 9 x 6 cm). Plexiglas transparent sheets for mice were used to reduce the size of the illuminated compartment to 12.5 x 14.5 x 7.0 cm.
Procedure
Habituation
The animals were submitted to two sessions in the activity chamber 24 h apart (training and test, respectively). During each session, the animal was allowed to freely explore the chamber for 5 min and the number of times the animal interrupted the light beams was computed at 2 and 5 min. The decrease in these exploration scores (number of beam interruptions) between the training and test sessions was taken as a measure of habituation (Platel and Porsolt, 1982) .
Inhibitory avoidance
In the training session, each mouse was placed individually in the illuminated compartment facing the closed door. After 10 s of adaptation, the light was turned on, the door was opened and the latency to enter the dark compartment was recorded. After entering the dark compartment, the animal received an unavoidable foot shock (0.5-mA, 1 s). Then the animal was immediately withdrawn from the apparatus and returned to its home cage. No animal took more than 120 s to enter the dark compartment in the training session. The test session, carried out 24 h later, was similar to the training session, except that the animal did not receive a foot shock and a maximum latency of 300 s was employed. The latency of entry into the dark compartment in the test session was taken as a measure of retention (Fujishiro et al., 2002) .
Statistical Analysis
Inhibitory avoidance test data were analyzed statistically by one-way ANOVA, followed by the Tukey Honest test when appropriate. The habituation was assessed by comparing session 1 behavior with session 2 behavior within the group using the two-tailed Student t test for repeated measures [15] . The locomotor effect of drugs was assessed by comparison among the treatments in session 1 of habituation and inhibitory avoidance (one-way ANOVA followed by the Tukey Honest test). The level of significance was set at p <0.05. All values are reported as mean ± SEM.
RESULTS
Habituation
As expected, the higher dose of diazepam (2.5 mg/kg) impaired the habituation of mice ( Fig. 1 ) since no inter-session decrement was seen at 2 (t = 0.04; df = 10; p>0.05) and 5 min (t = -0.02; df = 10; p>0.05). On the other hand, the lower dose of diazepam (1.0 mg/kg) and the vehicle caused a marked decrease in the locomotor activity between the training and test sessions (habituation) at 2 (diazepam 1.0: t = 8.03; df = 9; p<0.001; vehicle t = 4.67; df = 9; p<0.05) and 5 min (diazepam 1.0: t = 3.06; df = 9; p<0.05; vehicle: t = 2.86; df = 9; p<0.05). In the acute CPV experiment, the vehicle-treated mice showed habituation at 2 (t = 3.7; df = 9; p<0.001) and 5 min (t = 5.41; df = 9; p<0.001). CPV, however, gave contradictory results: although the higher dose (160 mg/kg) presented habituation at 2 (t = 2.97; df = 10; p<0.05) and 5 min (t = 2.49; df = 10; p<0.05), the lower dose (40 mg/kg) did not show any difference at 2 (t = 1.87; df = 10; p>0.05) or 5 min (t = 1.67; df = 10; p>0.05). (Fig. 2A) . No impairment of habituation was seen after repeated treatment (15 days) with CPV (Fig. 2B ).
There was a significant difference between the training and test session in mice treated with vehicle (2 min: t = 5.26; df = 8; p<0.001), CPV 40 mg/kg (2 min: t = 3.10; df = 7; p<0.05; 5 min: t = 3.17; df = 7; p<0.05), and CPV 160 mg/kg (2 min: t = 4.32; df = 11; p<0.05; 5 min: t = 4.67; df = 11; p<0.001). The 5 min measure of vehicle-treated mice did not reach the significance level in training vs. test comparison (t = 2.19; df = 8; p=0.059).
Inhibitory Avoidance
As expected, diazepam impaired memory in the inhibitory avoidance task (F 2,39 = 3.59; p<0.05; Fig.  3 , upper panel). The higher diazepam dose (2.5 mg/kg), administered before the training session, significantly reduced the latency to enter the dark compartment in the test session (p<0.05, Tukey).
On the other hand, neither dose of the CPV (40-160 mg/kg) changed the latency to enter the dark compartment in the test session (F 2,33 = 1.65; p>0.05; Fig. 3 Fig. 3 , lower panel).
Locomotor activity
Since diazepam and CPV did not change the number of beam interruptions in the training session for habituation or escape latency in the training session for inhibitory avoidance, it was concluded that these compounds, at the doses used here, did not alter locomotor activity.
DISCUSSION
The main result of the present study was that the phytotherapeutic compound of V officinalis and P alata did not present the memory impairment exhibited by diazepam in animal models. Thus, while diazepam impaired the habituation and performance in the step-through inhibitory avoidance, indicating an amnesic effect, the CPV (acute or repeated) did not alter the behavior on these learning tasks. However, the data obtained here do present some problems. The results for the acute effect of CPV could be considered contradictory since the mice treated with the CPV lower dose did not show any habituation, while this was observed in the mice treated with the CPV higher dose. This could indicate a U-shaped dose-response curve for the CPV. However, the CPV did not impair the performance in the test session for inhibitory avoidance. Thus, in order to clarify this point, the CPV data was further explored using the habituation data (training score minus test score) analysis (Kopf and Baratti, 1996) . Using this methodology, no significant differences in the habituation were found among the treatments in acute and chronic paradigms at 2 (F2,29 = 1.0; p>0.05) or 5 (F2,29 = 2.4; p>0.05) min. Thus, it A B was concluded that memory impairment in this task was absent after acute CPV treatment.
Other point that deserved the discussion was that, in the test session in the inhibitory avoidance, the values for diazepam (Fig. 3A right) and CPV 160 (3B right) were similar, which could cause some doubt about the absence of impairment of CPV at this dose. However, compared to vehicle groups, while diazepam impaired the performance, CPV had no effect. This stressed the importance of concurrent control animals. It should be stressed that these effects were found without any effect on locomotor activity. The absence of locomotor impairment at the dose used here was in accordance with the data obtained with the rats submitted to the open-field test in which impairment was seen only at doses above 300 mg/kg p.o. . The anxiolytic effect in the elevated plus-maze was seen after repeated (14 days) treatment with CPV 20 mg/mg , a dose much lower than the sedative dose, which suggested a wide dose range for the CPV anxiolytic effect. Although there are studies indicating an anxiolytic effect of V officinalis and Passiflora (Akhondzadeh et al., 2001; Dhawan et al., 2001a; Dhawan et al., 2001b; Andreatini et al., 2002; Dhawan et al., 2004) , data for a possible memory effect are scarce. Moreover, some neurochemical effects have been associated with this anxiolytic effect. The valerian extract or some of its constituents, such as valerenic acid, exhibits some actions that, like the benzodiazepines, increase the GABA transmission (direct action on GABA A receptors, decreased GABA metabolism or reuptake), which may contribute to its anxiolytic effect (Wong et al., 1998; Houghton, 1999; Ortiz et al., 1999) . However, in the present study, the CPV did not induce any memory impairment, which was contrary to expectations for this GABA enhancement action of valerian. On the other hand, the absence of amnesic effect of CPV was in accordance with the literature with no reports of deleterious effects on cognition or psychomotor performance in the clinical studies with valerian or valepotriates (Andreatini et al., 2002; Kuhlman et al., 1999; Glass et al., 2003; Hallam et al., 2003; Gutierrez et al., 2004) . To explain this paradox, it was postulated that the behavioral effect of the phytomedicines could be due to a synergistic interaction between its constituents (Della-Loggia et al., 1981; Williamson, 2001) . Thus, it could be hypothesized that some other constituents of CPV could neutralize this deleterious effect on memory. Another possibility would be that the CPV acted selectively at GABA-A subtype, like alpha-2 subunit, which would be associated to anxiolytic effect without memory impairment (Mohler et al., 2002) . Passiflora alata Dryander exerts an anxiolytic effect on performance in the elevated plus-maze (Petry et al., 2001) , an effect that could be related to the presence of flavonoids, such as chrysin and apigenin (Paladini et al., 1999) . This chemical group, chrysin and apigenin in particular, has a putative partial agonist action on the benzodiazepine receptor and exhibits an anxiolytic-like effect in animal models (Wolfman et al., 1994; Salgueiro et al., 1997; Paladini et al., 1999; Zanoli et al., 2000; Petry et al., 2001) . It is interesting to note that the CPV profile (anxiolytic effect without memory impairment) is compatible with a partial agonist benzodiazepine action (Lader, 1995) . This same behavioral profile was also found for chrysin and apigenin: an anxiolytic effect in the elevated plus-maze without impairment of the habituation and inhibitory avoidance (Wolfman et al., 1994; Salgueiro et al., 1997; Paladini et al., 1999) . However, the anxiolytic effect of Passiflora incarnata was not due to any known phytoconstituents, including chrysin (Dhawan et al., 2004; Soulimani et al., 1997) . In this line, it was interesting to note that the central nervous system effects of Passiflora incarnata was related to a tri-substituted benzoflavone moiety isolated from methanol extract of this plant (Dhawan et al., 2004) . Although the present results are mainly negative, their importance lies in differentiating the adverse profile of the putative anxiolytic compound from the standard anxiolytics benzodiazepines and, in the future, it may become a pharmacological alternative for the treatment of generalized anxiety disorder.
In conclusion, the acute and repeated administration of a compound combining V officinalis and P alata extracts did not appear to produce the memory impairment in the habituation and inhibitory avoidance in mice. Although these results suggested an absence of amnesic effect of the compound, the present data need to be confirmed in other animal memory tasks and by the clinical trials. 
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